The Novel Drugs of 2014 –Record Approvals for Niche Markets

DOI:

https://doi.org/10.37285/ijpsn.2015.8.3.1

Authors

  • D Samba Reddy

Abstract

In 2014, 41 new drugs were approved by the FDA, the highest approval in two decades. This number was 52% higher than the 27 approvals in 2013, indicating another year of excellent innovation and productivity. Seventeen drugs (41%) were First-in-Class with a new or unique mechanism of action for treating a disease. Moreover, 17 of 41 (41%) of these novel drugs were for the treatment of rare diseases, a testament to continued focus or shift to niche diseases. The U.S. FDA is the leading authority for drug approvals worldwide. Many schemes and tracks at the FDA have led to accelerated approval of novel drugs. Such reviews as fasttrack or breakthrough designation are established for meeting demand more quickly. Despite such historic drug approvals, there is continued productivity crisis in R & D due to steady cost escalation for drug discovery and development. The U.S. pharmaceutical market is forecasted to increase from an estimated value of $395 billion in 2014 to reach $548 billion by 2020. The prices appear to be increasing faster for branded prescription drugs. Overall, the current drug approvals and trends clearly reveal the pharma industry shift to niche diseases for pricing power and return on investment. 

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

New drugs, NMEs, Biologics, Fast-track, First-in-class, Orphan drugs

Downloads

Published

2015-08-30

How to Cite

1.
Reddy DS. The Novel Drugs of 2014 –Record Approvals for Niche Markets. Scopus Indexed [Internet]. 2015 Aug. 30 [cited 2024 Dec. 10];8(3):2889-93. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/780

Issue

Section

Review Articles

References

Blank C (2015). FDA Approved more than 40 Novel Drugs in 2014. Drug Topics, February 2.

FDA (2014). Novel New drugs 2014 Summary. CDER, FDA Brochure, January, pp-1-20.

Jarvis LM (2015). The Year in New Drugs. Chemical and Engineering News. 93(5): 11-16.

Mancano MA (2015). New Drugs of 2014. Part I and II. Pharmacy Times; January/ February.

Reddy DS (2012). Novel New Drug approvals in 2011: A succinct Analysis of Drug Discovery Trends in the United States. Int J Pharm Sci Nanotech. 5(2): 1661-1665.

Reddy DS (2013). New Drugs of 2012: A Concise overview of the Names and Trends for Innovative Brand Market in the United States. Int J Pharm Sci Nanotech. 6(2): 2009-2013.

Reddy DS (2014). An overview of Novel Drugs and New Chemical Entities in 2013. Int J Pharm Sci Nantotech. 7(3): 2505-2508.

Reddy DS and Woodward R (2004). Ganaxolone: A Perspective overview. Drugs Future. 29: 227-242.

Scannell JW, Blanckley A, Helen Boldon H, and Warrington B (2012). Diagnosing the Decline in Pharmaceutical R and D Efficiency. Nature Rev Drug Discovery. 11: 191-200

Most read articles by the same author(s)

1 2 > >>